Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64417184 in healthy volunteers and RSV challenge
NCT03403348Phase 1Completed
- Sponsor
- Johnson & Johnson
- Start
- May 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-64417184 in respiratory syncytial virus infection (RSV) (7 arms), sponsored by Johnson & Johnson. Primary endpoints: Number of Participants With Adverse Events (AEs) up to 8 months, Number of Participants With Laboratory Abnormalities up to 8 months and 6 more. Started May 2018; status: completed.
02
Drugs
JNJ-64417184
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03403348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03403348.